More recently, using a combination of connectivity mapping in a conditional model of Mixed-Lineage Leukemia (MLL) AML and drug similarity analysis, we identified FDA-approved candidate drugs (including Salinomycin, Atorvastatin, and Vidofludimus) that potentially target HOXA-dependency in MLL-AF9 leukemia [14]. This evidence concerns the gene MLLT3 and acute myeloid leukemia.